Literature DB >> 26018690

Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT.

Hossein Jadvar1, Kai Chen, Osamu Ukimura.   

Abstract

We report on a 61-year-old man with elevated serum prostate-specific antigen level of 10.5 ng/mL who had undergone prior negative standard transrectal ultrasound biopsy at another institution. He was referred to our medical center for evaluation and underwent a clinical 3-T multiparametric MRI and a research protocol PET/CT with the cellular proliferation radiotracer (18)F-FMAU (2'-deoxy-2'-[(18)F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil). The PET/CT and multiparametric MRI were fused with transrectal ultrasound images for real-time hybrid image-based targeting of the biopsy needle. PET/CT with (18)F-FMAU was helpful in localizing the nonstandard biopsy sites that on histopathology revealed suspected tumor deposits.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26018690      PMCID: PMC4494895          DOI: 10.1097/RLU.0000000000000814

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

Review 1.  Intraprostatic targeting.

Authors:  Osamu Ukimura; Kenneth Faber; Inderbir S Gill
Journal:  Curr Opin Urol       Date:  2012-03       Impact factor: 2.309

Review 2.  Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.

Authors:  Osamu Ukimura; Jonathan A Coleman; Alex de la Taille; Mark Emberton; Jonathan I Epstein; Stephen J Freedland; Gianluca Giannarini; Adam S Kibel; Rodolfo Montironi; Guillaume Ploussard; Monique J Roobol; Vincenzo Scattoni; J Stephen Jones
Journal:  Eur Urol       Date:  2012-09-25       Impact factor: 20.096

3.  Automated synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module.

Authors:  Zibo Li; Hancheng Cai; Peter S Conti
Journal:  Nucl Med Biol       Date:  2010-12-03       Impact factor: 2.408

Review 4.  PET imaging of proliferation with pyrimidines.

Authors:  Omid S Tehrani; Anthony F Shields
Journal:  J Nucl Med       Date:  2013-05-14       Impact factor: 10.057

Review 5.  Imaging of cell proliferation: status and prospects.

Authors:  James R Bading; Anthony F Shields
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

6.  [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations.

Authors:  Hossein Jadvar; Li-Peng Yap; Ryan Park; Zibo Li; Kai Chen; Lindsey Hughes; Aida Kouhi; Peter Conti
Journal:  Mol Imaging       Date:  2012 Sep-Oct       Impact factor: 4.488

Review 7.  Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography.

Authors:  Hossein Jadvar
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015
  7 in total
  6 in total

1.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

Review 2.  PET Molecular Imaging-Directed Biopsy: A Review.

Authors:  Baowei Fei; David M Schuster
Journal:  AJR Am J Roentgenol       Date:  2017-05-15       Impact factor: 3.959

3.  Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice.

Authors:  Hossein Jadvar; Ryan Park; Li-Peng Yap; Kai Chen; Lindsey Hughes; Peter Conti
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

Review 4.  PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

Review 5.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

6.  AOJNMB is Indexed in PubMed Central from the First Issue.

Authors:  S Rasoul Zakavi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2017
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.